2nd Annual Hemophilia Drug Development Summit
Evvnt Promotion / evvnt
Archive
20.08.2019 - 22.08.2019 Wyndham Boston Beacon Hill, 5 Blossom Street, 02114 Boston, USA
Time: 8:00 am - 5:00 pm
Conference themes
Given the excitement and anticipation of increasingly more promising prophylactic treatments and gene therapies, the 2nd Annual Hemophilia Drug Development Summit, once again unites leading pharma, biotech and academic KOLs working to translate and clinically develop longer acting and more efficacious therapies to overcome significant unmet medical need and hemophilia and other bleeding disorders.
Given the excitement and anticipation of increasingly more promising prophylactic treatments and gene therapies, the 2nd Annual Hemophilia Drug Development Summit, once again unites leading pharma, biotech and academic KOLs working to translate and clinically develop longer acting and more efficacious therapies to overcome significant unmet medical need and hemophilia and other bleeding disorders.
Professional congress organizer (PCO)
Hanson Wade
Hanson Wade
Notes
Brochure: https://go.evvnt.com/411348-2?pid=4832
Speakers: Howard Levy, Chief Medical Officer, Catalyst Biosciences, H. Trent Spencer,President, Expression Therapeutics
Brochure: https://go.evvnt.com/411348-2?pid=4832
Speakers: Howard Levy, Chief Medical Officer, Catalyst Biosciences, H. Trent Spencer,President, Expression Therapeutics
Enquiries and Registration:
https://go.evvnt.com/411348-0?pid=4832
Mr. Ilektra Stouka
Health Services, Public Health
Languages
English
English
Congress fees
USD 3.697,00
(USD 1499.0 - USD 3697.0)
USD 3.697,00
(USD 1499.0 - USD 3697.0)
Organizer contact info
83 Great Titchfield Street
W1W 6RH London
United Kingdom
83 Great Titchfield Street
W1W 6RH London
United Kingdom
"Going International promotes access to education and training for all regardless of social, geographic and national borders."